These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 9923859)

  • 1. Induction of tumor antigen-specific immunity in vivo by a novel vaccinia vector encoding safety-modified simian virus 40 T antigen.
    Xie YC; Hwang C; Overwijk W; Zeng Z; Eng MH; Mulé JJ; Imperiale MJ; Restifo NP; Sanda MG
    J Natl Cancer Inst; 1999 Jan; 91(2):169-75. PubMed ID: 9923859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A safety-modified SV40 Tag developed for human cancer immunotherapy.
    Tseng-Rogenski SS; Arredouani MS; Escara-Wilke JF; Neeley YC; Imperiale MJ; Sanda MG
    Drug Des Devel Ther; 2009 Feb; 2():17-24. PubMed ID: 19920890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.
    Neeley YC; Arredouani MS; Hollenbeck B; Eng MH; Rubin MA; Sanda MG
    Prostate; 2008 May; 68(7):715-27. PubMed ID: 18302222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitation of CD8(+) T-lymphocyte responses to multiple epitopes from simian virus 40 (SV40) large T antigen in C57BL/6 mice immunized with SV40, SV40 T-antigen-transformed cells, or vaccinia virus recombinants expressing full-length T antigen or epitope minigenes.
    Mylin LM; Schell TD; Roberts D; Epler M; Boesteanu A; Collins EJ; Frelinger JA; Joyce S; Tevethia SS
    J Virol; 2000 Aug; 74(15):6922-34. PubMed ID: 10888631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy of SV40 induced tumours in mice: a model for vaccine development.
    Bright RK; Shearer MH; Pass HI; Kennedy RC
    Dev Biol Stand; 1998; 94():341-53. PubMed ID: 9776255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin.
    Hsieh CJ; Kim TW; Hung CF; Juang J; Moniz M; Boyd DA; He L; Chen PJ; Chen CH; Wu TC
    Vaccine; 2004 Sep; 22(29-30):3993-4001. PubMed ID: 15364449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of a subdominant H-2Kd-restricted SV40 tumor antigen cytotoxic T lymphocyte epitope in tumor rejection.
    Newmaster RS; Mylin LM; Fu TM; Tevethia SS
    Virology; 1998 May; 244(2):427-41. PubMed ID: 9601511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD4+ T lymphocytes play a critical role in antibody production and tumor immunity against simian virus 40 large tumor antigen.
    Kennedy RC; Shearer MH; Watts AM; Bright RK
    Cancer Res; 2003 Mar; 63(5):1040-5. PubMed ID: 12615720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC.
    Neeley YC; McDonagh KT; Overwijk WW; Restifo NP; Sanda MG
    Prostate; 2002 Nov; 53(3):183-91. PubMed ID: 12386918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunization of BALB/c mice with recombinant simian virus 40 large tumor antigen induces antibody-dependent cell-mediated cytotoxicity against simian virus 40-transformed cells. An antibody-based mechanism for tumor immunity.
    Bright RK; Shearer MH; Kennedy RC
    J Immunol; 1994 Sep; 153(5):2064-71. PubMed ID: 8051411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4+ T lymphocytes are critical mediators of tumor immunity to simian virus 40 large tumor antigen induced by vaccination with plasmid DNA.
    Aldrich JF; Lowe DB; Shearer MH; Winn RE; Jumper CA; Bright RK; Kennedy RC
    J Virol; 2011 Jul; 85(14):7216-24. PubMed ID: 21593176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-tumor immunity elicited by a recombinant vaccinia virus expressing CD70 (CD27L).
    Lorenz MG; Kantor JA; Schlom J; Hodge JW
    Hum Gene Ther; 1999 May; 10(7):1095-103. PubMed ID: 10340542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the same gene.
    Chen CH; Wang TL; Ji H; Hung CF; Pardoll DM; Cheng WF; Ling M; Wu TC
    Gene Ther; 2001 Jan; 8(2):128-38. PubMed ID: 11313782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of simian virus 40 large T antigen recombinant protein and DNA immunization in the induction of protective immunity from experimental pulmonary metastasis.
    Watts AM; Shearer MH; Pass HI; Bright RK; Kennedy RC
    Cancer Immunol Immunother; 1999 Feb; 47(6):343-51. PubMed ID: 10203065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection against a lethal challenge with SV40-transformed cells by the direct injection of DNA-encoding SV40 large tumor antigen.
    Bright RK; Beames B; Shearer MH; Kennedy RC
    Cancer Res; 1996 Mar; 56(5):1126-30. PubMed ID: 8640771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of humoral immune responses and tumor immunity in mice immunized with recombinant SV40 large tumor antigen and a monoclonal anti-idiotype.
    Shearer MH; Bright RK; Kennedy RC
    Cancer Res; 1993 Dec; 53(23):5734-9. PubMed ID: 7694794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunity in strain 2 guinea-pigs inoculated with vaccinia virus recombinants expressing varicella-zoster virus glycoproteins I, IV, V or the protein product of the immediate early gene 62.
    Lowry PW; Solem S; Watson BN; Koropchak CM; Thackray HM; Kinchington PR; Ruyechan WT; Ling P; Hay J; Arvin AM
    J Gen Virol; 1992 Apr; 73 ( Pt 4)():811-9. PubMed ID: 1321876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor immunity against a simian virus 40 oncoprotein requires CD8+ T lymphocytes in the effector immune phase.
    Lowe DB; Shearer MH; Jumper CA; Bright RK; Kennedy RC
    J Virol; 2010 Jan; 84(2):883-93. PubMed ID: 19889780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus.
    Kass E; Schlom J; Thompson J; Guadagni F; Graziano P; Greiner JW
    Cancer Res; 1999 Feb; 59(3):676-83. PubMed ID: 9973217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.